Menu
Menu
BOSTON, MA, November 11, 2025 – Complete Genomics, a leading innovator in genomic sequencing, today announced a collaboration with SOPHiA GENETICS (NASDAQ: SOPH), a global leader in AI-driven precision medicine, to launch and co-market MSK-ACCESS® and MSK-IMPACT® powered with SOPHiA DDM™ on Complete Genomics’ DNBSEQ-T1+ sequencing platform. The companies aim to broaden access to precision oncology testing by offering the best-in-class liquid biopsy and solid tumor applications to customers globally. The announcement was made from the Association for Molecular Pathology (AMP) Annual Meeting in Boston.
The collaboration integrates SOPHiA GENETICS’ advanced, AI-powered applications MSK-IMPACT® and MSK-ACCESS® powered by SOPHiA DDM™, developed in collaboration with Memorial Sloan Kettering Cancer Center (MSK), with Complete Genomics’ newly launched DNBSEQ-T1+ sequencing platform. Together, Complete Genomics and SOPHiA GENETICS will provide an integrated, sample-to-report workflow for laboratories, marking a significant expansion of their partnership into the precision oncology research market.
“Pairing MSK-IMPACT® and MSK-ACCESS® powered with SOPHiA DDM™ with our DNBSEQ-T1+ platform creates a powerful and accessible solution for laboratories looking to scale high-quality cancer genomic profiling,” said Rob Tarbox, vice president of product and marketing at Complete Genomics. “By combining MSK’s rigorously validated assays, SOPHiA GENETICS’ robust analytics, and our sequencing technology, we are enabling decentralized labs to deliver faster, more accurate, and more affordable insights to clinicians and researchers.”
“This collaboration underscores SOPHiA GENETICS’ commitment to broadening access to data-driven medicine,” said Ross Muken, President,SOPHiA GENETICS. “Partnering with Complete Genomics to streamline use of MSK-IMPACT® and MSK-ACCESS® powered with SOPHiA DDM™ on the DNBSEQ-T1+ platform enables more laboratories around the world to adopt precision oncology through scalable, end-to-end genomic solutions.”
The DNBSEQ-T1+, powered by proprietary DNBSEQ technology, delivers Q40-level accuracy, optimized throughput from 500 million to 2 billion reads per flow cell. Each flow cell is able to be run independently, with a 24-hour paired-end 150bp run time, offering laboratories a cost-effective and highly flexible sequencing solution. At maximum throughput, each T1+ flow cell can run up to 60 tumor-normal sample pairs for tissue, up to 16 tumor-normal sample pairs for liquid biopsy.
SOPHiA DDM™ is a technology-agnostic analytics platform that leverages AI to compute, standardize, and analyze healthcare data. Joint evaluation of MSK-IMPACT® and MSK-ACCESS® on the DNBSEQ-T1+ platform demonstrated highly concordant variant calls and allele frequencies compared with equivalent sequencing systems, while achieving lower background noise, reduced turnaround time, and seamless compatibility with existing SOPHiA DDM™ workflows.
This new offering provides clinical laboratories, cancer centers, and drug developers with a high-performance, cost-efficient path to implementing comprehensive genomic profiling for precision oncology research.
To learn more, visit the Complete Genomics Booth 1210 or SOPHiA GENETICS Booth 921 at AMP from November 11–15, 2025 or visit www.CompleteGenomics.com and www.SOPHiAGENETICS.com.
About Complete Genomics
Complete Genomics is a pioneering life sciences company that provides novel, complete sequencing solutions including sample/library preparation, lab automation, sequencing, and data analysis. The sequencing portfolio offers a full lineup of sequencers ranging from low, medium, and high throughput capacities, all powered by its proprietary DNBSEQ technology. More than 10,900 publications are based on DNBSEQ technology across a wide array of applications. To learn more, visit www.completegenomics.com.
* For Research Use Only. Not for use in diagnostic procedures.
Boston, MA and San Diego, CA, November 11, 2025 – SOPHiA GENETICS (NASDAQ: SOPH), a global leader in AI-driven precision medicine, and Element Biosciences, Inc., a biology company transforming the pace and accessibility of scientific discovery, today announced at the Association for Molecular Pathology (AMP) Annual Meeting a partnership that unites sequencing and AI analytics to streamline genomic workflows and accelerate the research supporting precision medicine.
This collaboration integrates SOPHiA GENETICS’ AI-powered analytics platform, SOPHiA DDM™, with Element’s AVITI24™ 5D multiomic and AVITI™ sequencing systems to deliver a seamless, end-to-end workflow for next-generation sequencing (NGS). Together, the technologies will provide speed, scalability, and flexibility, enabling clinical researchers to turn NGS data into actionable insights within a single streamlined process. AVITI and AVITI24 users will also gain access to the full suite of SOPHiA DDM™ applications in oncology and rare disease, expanding the analytical power of their sequencing workflows.
Professor Hagay Sobol, Head of the Molecular Oncogenetics Laboratory at the Institut Paoli-Calmettes (IPC), said: “We believe that combining the Element AVITI system with the SOPHiA DDM™ Platform has the potential to transform the way our lab approaches genomic testing by seamlessly delivering highly accurate results. We expect this collaboration that pairs SOPHiA GENETICS’ powerful analytics with Element’s sequencing performance will be able to deliver the consistency and scalability needed for research that helps bring precision medicine to more patients, faster.” IPC is a comprehensive cancer center in Marseille, France, specializing in cancer research, treatment, and teaching.
Jurgi Camblong, CEO and Co-Founder of SOPHiA GENETICS, said: “Integrating our universal platform with leading sequencing technologies such as the Element AVITI system allows healthcare organizations, regardless of size or geography, to adopt innovative, AI-driven technologies while keeping genomic research local. This partnership aligns with our shared goals of democratizing access to research that supports precision medicine globally, bringing data-driven decisions closer to home, and extending the reach of our respective technologies.”
Molly He, CEO and Co-Founder of Element Biosciences, said: “Pairing Element’s cutting-edge AVITI and AVITI24 systems with SOPHiA GENETICS’ powerful AI analytics is a game-changer for the genomics community. This collaboration doesn’t just streamline workflows - it redefines what’s possible in sequencing, delivering richer insights, faster results and unprecedented accessibility. Together, we’re breaking down barriers to enable the future of precision medicine and empower every lab, everywhere, to do more with their data.”
About the technology
SOPHiA DDM™ is a technology-agnostic analytics platform that leverages AI to compute, standardize and analyze healthcare data. Since its inception, SOPHiA GENETICS has been committed to ensuring compatibility across all technologies. Through this partnership, laboratories can process datasets of any size, retain full control of their data, and scale efficiently as precision medicine adoption accelerates worldwide.
Element Biosciences’ AVITI24 5D Multiomic and AVITI next generation sequencing systems are designed to make high-performance genomics accessible to all. With its combination of accuracy, flexibility, and cost efficiency, Element empowers laboratories to scale with confidence and accelerate the researching driving precision medicine worldwide.
To learn more about the partnership or SOPHiA GENETICS, connect with the team at booth 921 at AMP in Boston, Massachusetts from November 11 – 15 or visit SOPHiAGENETICS.com.
ROLLE AND TOKYO, October 16, 2025 – A.D.A.M. Innovations, Japan's leading private genetic testing company, and SOPHiA GENETICS (Nasdaq: SOPH), an AI technology company pioneering data-driven medicine, today announced at ESMO a strategic agreement to bring cutting-edge liquid biopsy genomic testing to the Japanese population. The companies will also partner to commercialize a liquid biopsy companion diagnostic aimed at advancing personalized and precision cancer care in Japan.
As a market leader for genetic testing in Japan with a high-throughput laboratory located in central Tokyo, A.D.A.M. Innovations has served the Japanese population for over 20 years and completed over 2.8 million genomic tests to-date. A.D.A.M. Innovations will continue its legacy of bringing global innovations to Japan by adopting the AI-powered SOPHiA DDM™ Platform to advance personalized cancer testing across the country.
The partnership will initially focus on launching the liquid biopsy application, MSK-ACCESS® powered with SOPHiA DDMTM. This innovative liquid biopsy test is designed to detect actionable genomic alterations from a single blood draw, leveraging state-of-the-art AI to analyze circulating tumor DNA (ctDNA) in a minimally invasive manner. The test utilizes a matched tumor-normal approach which improves accuracy and avoids false positives. By launching the test locally and analyzing samples in-house, A.D.A.M. Innovations will expedite testing turnaround times, reduce costs to patients, and advance local cancer research.
As part of the partnership, the companies also aim to develop a liquid biopsy companion diagnostic (CDx) test in Japan. By developing the application into a CDx, more patients can gain access to the benefits of the high-quality tumor profiling test, advancing personalized healthcare at scale. The offering will also provide pharmaceutical partners with a powerful new tool to accelerate drug development and market access in Japan. The companies will collaborate across all steps of the development process, with A.D.A.M. Innovations leveraging its deep clinical and regulatory expertise to support regulatory submissions in Japan.
“Making precision oncology more accessible to patients in Japan is a significant milestone,” said Ross Muken, President, SOPHiA GENETICS. “By combining A.D.A.M. Innovations’ strong clinical expertise and local presence with the global reach of the SOPHiA DDM™ Platform, we can drive the nationwide adoption of data-driven medicine, advancing both clinical research and the delivery of personalized oncology care.”
“For over two decades, we have supported academic, research and medical institutions with advanced clinical genomic testing,” commented Michel Mommejat, President of A.D.A.M. Innovations. “Through our partnership with SOPHiA GENETICS and its AI-driven platform, we are taking a major step forward in accelerating precision oncology across Japan. Testing locally enables faster turnaround times, reduces costs, enhances patient care, and supports global CDx deployments.”
The collaboration was formally announced from the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin. The announcement underscores both companies’ shared commitment to advancing data-driven and liquid biopsy-based solutions for cancer care in Japan. Learn more by connecting with SOPHiA GENETICS and A.D.A.M. Innovations at ESMO booth #2039 from October 17-21, 2025.
For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.COM, or connect on LinkedIn.
For more information on A.D.A.M. Innovations, visit ADAM-INNOVATIONS.COM or connect on LinkedIn.
Boston, MA and Rolle, Switzerland – October 16, 2025 — SOPHiA GENETICS (Nasdaq: SOPH), a leader in AI-driven precision medicine, today announced the launch of SOPHiA DDM™ Digital Twins, a breakthrough research technology that creates dynamic, virtual representations of individual patients to simulate potential outcomes and help oncologists make better treatment decisions.
SOPHiA DDM™ Digital Twins uses each patient’s unique clinical, biological, imaging, and genomic data to generate a computational replica of the patient and their individual disease. Oncologists can use the virtual replica of the patient, or Digital Twin, to simulate treatment responses, disease trajectories, and survival outcomes in real time, and to explore potential treatment strategies virtually before making decisions at the bedside.
“Digital twin technology enables integrative visualization of multimodal oncologic data, revealing latent correlations across modalities. By simulating disease trajectories and therapeutic responses within a virtual environment, Digital Twins offer a framework for in silico experimentation, supporting anticipatory and individualized clinical decision-making,” said Dr. Pierre Heudel, Medical Oncologist, Centre Léon Bérard.
“This breakthrough technology represents an important step forward in helping clinicians make more informed decisions for complex cancers,” said Dr. Clara Montagut, Head of Gastrointestinal Cancer, Hospital del Mar. “Having a digital model that can simulate potential outcomes before treatment has the potential to be transformative in how we deliver future care.”
Digital Twins leverages the collective intelligence of the SOPHiA GENETICS community and a robust, multimodal, longitudinal dataset to simulate potential therapy response. The tool equips clinicians with insights derived from a broad network of global patient cases by breaking down institutional and geographic barriers and enabling clinicians to tap into a global intelligence to enhance decision making.
“Building on advances from preclinical and clinical research, digital-twin technology offers new avenues to enhance the diagnosis and management of complex diseases, including cancer. SOPHiA DDM™ Digital Twins provides clinicians and researchers with a robust, data-driven framework for hypothesis testing and may represent a meaningful step toward broader implementation of precision medicine,” noted Dr. Ernest Nadal, Director of Research and Innovation, Catalan Institute of Oncology.
Dr. Mariano Provencio Pulla, Head of the Medical Oncology Department, Puerta de Hierro University Hospital, added, “The Digital Twins concept developed by SOPHiA GENETICS is really a breakthrough in oncology. We absolutely need this approach to take full advantage of major progress that has been made in clinical care in recent years, especially in the context of pre-surgical immunotherapy for patients with non-small cell lung cancer eligible for surgery. I truly believe that it is the future of data-driven medicine.”
Powered by state-of-the-art artificial intelligence, SOPHiA DDM™ Digital Twins continuously evolves as new data becomes available, strengthening accuracy and research capabilities over time. The tool also generates synthetic data that reflects real-world disease patterns, enabling researchers to explore additional therapeutic paths and model potential outcomes before committing to a treatment strategy.
“Cancer is constantly evolving, and static snapshots are no longer enough,” said Jurgi Camblong, Ph.D., Co-Founder & CEO, SOPHiA GENETICS. “With SOPHiA DDM™ Digital Twins, we can create advanced AI models based on our broad patient network, accelerating research, sharpening clinical decisions, and turning today’s insights into tomorrow’s breakthroughs. This reflects our ambition to make data-driven medicine the global standard of care.”
SOPHiA DDM™ Digital Twins brings key features that could, in the future, reshape precision oncology:
This launch marks a new era in precision oncology, one where technology empowers physicians to move beyond retrospective evidence and toward forward-looking, AI-powered decision support tailored to each patient. Digital Twins is launching on the SOPHiA DDMTM Platform for lung cancer, with more cancer types available in the coming months.
To learn more about Digital Twins or SOPHiA GENETICS, connect with the team at ESMO in Berlin, Germany from October 17 – 21 or visit SOPHiAGENETICS.COM.
SALT LAKE CITY AND BOSTON, MA - September 23, 2025 – Myriad Genetics (Nasdaq: MYGN), a leader in molecular diagnostic testing and precision medicine, and SOPHiA GENETICS (Nasdaq: SOPH), an AI technology company transforming precision medicine, announced a strategic collaboration to develop and provide pharmaceutical companies with an innovative global liquid biopsy companion diagnostic (CDx) test. This partnership will leverage Myriad’s advanced laboratory capabilities in the U.S. to support global testing for clinical trials and SOPHiA GENETICS’ broad, decentralized network of more than 800 connected institutions in more than 70 countries for global test deployment.
“Serving patients and healthcare providers along the cancer care continuum is a strategic focus for Myriad Genetics,” said Sam Raha, President and CEO, Myriad Genetics. "We expect this collaboration with SOPHiA GENETICS to support the development and global commercialization of comprehensive CDx solutions for our BioPharma partners with the potential to positively impact patient lives, add an important product offering to the Myriad menu and support the growth of our CDx programs."
SOPHiA GENETICS and Myriad will initially focus on the liquid biopsy application, MSK-ACCESS® powered with SOPHiA DDM™. Developed in collaboration with Memorial Sloan Kettering Cancer Center, MSK-ACCESS® powered with SOPHiA DDM™ is an innovative liquid biopsy test that detects actionable genomic alterations from a single blood draw using proprietary, state-of-the-art algorithms which analyze circulating tumor DNA (ctDNA). By developing the application into a CDx, more patients can gain access to the benefits of this high-quality tumor profiling test, advancing personalized healthcare at scale.
Myriad will pursue regulatory submissions in the U.S., and SOPHiA GENETICS will manage regulatory submissions outside of the U.S. Both companies will collaborate across development activities. This innovative, hybrid approach is expected to provide pharmaceutical partners with access to key regulated markets globally.
“This collaboration represents a pivotal moment for the industry,” said Jurgi Camblong, Co-founder and CEO of SOPHiA GENETICS. “By combining the complementary strengths of a specialty lab leader and a global testing network, we are not only expanding access to innovative oncology testing but also laying the foundation for a new hybrid model in companion diagnostics. This collaboration will allow us to serve both clinical and pharmaceutical partners better, while accelerating the adoption of liquid biopsy solutions across key markets.”
SOPHiA GENETICS and Myriad will participate in a panel discussion at the World CB and CDx Summit in Boston and provide additional details on the collaboration.
BOSTON, MA - September 22, 2025 – SOPHiA GENETICS (Nasdaq: SOPH), an AI technology company transforming precision medicine, today announced an expansion of its collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) from the World CB & CDx Summit in Boston. The companies aim to improve the diagnosis and treatment of breast and prostate cancer by developing an optimized next generation sequencing (NGS) solution that leverages SOPHiA GENETICS’s AI algorithms to detect genetic mutations in the PIK3CA/AKT1/PTEN pathway.
The PIK3CA/AKT1/PTEN pathway is a key molecular signaling network that regulates how cells grow and survive, and its disruption is linked to the development of many cancers, including breast and prostate cancer. The PTEN gene, when altered, can contribute to cancer development and resistance to treatment. As part of this collaboration, the companies have developed an optimized NGS solution that deploys AI agents to analyze and detect genomic mutations across the full PTEN gene. A prototype of the enhanced solution has already demonstrated improved sensitivity in its ability to detect complex mutations across the pathway.
As part of the agreement, SOPHiA GENETICS will roll out a Privileged Access Program to selected clinical laboratories specializing in breast and prostate cancer research to validate sensitivity in a real-world setting, with broader commercial availability expected in 2026, alongside a multi-center real-world evidence study to further test its effectiveness. SOPHiA GENETICS’s global network will also help drive adoption of advanced PIK3CA/AKT1/PTEN testing in both tissue and liquid biopsy to expand patient access to precision therapies.
“Each day brings new insights that transform our understanding of cancer. Partnering with innovative biopharma leaders like AstraZeneca allows us to translate these discoveries into action for breast and prostate cancer patients worldwide, representing another step forward in our mission to democratize data-driven medicine.” said Ross Muken, President, SOPHiA GENETICS.
The expanded partnership highlights the shared commitment of SOPHiA GENETICS and AstraZeneca to drive innovation in precision oncology and to ensure that patients across the globe can benefit from advanced genomic testing and targeted treatments. To learn more, connect with SOPHiA GENETICS at the World CB & CDx Summit in Boston, MA from September 22-25, 2025
For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.COM, or connect on LinkedIn.
ROLLE, Switzerland - September 17, 2025 – SOPHiA GENETICS (Nasdaq: SOPH), an AI technology company transforming precision medicine, announced that it has joined NAIPO (National AI Initiative for Precision Oncology), a new national initiative aimed to develop a secure, Swiss-hosted infrastructure to enable AI-enhanced precision oncology across Switzerland.
According to the Global Cancer Observatory, cancer remains one of the country’s most pressing public health challenges, with nearly 58,000 new cases and close to 20,000 deaths recorded in 2022. Achieving fully personalized care remains challenging due to fragmented data and limited integration across institutions. A closer coordination across the national healthcare network will result in more effective and equitable treatments for patients.
NAIPO responds to this need with an integrated, AI-powered precision oncology platform to transform cancer care delivery. By applying advanced AI models at every stage of the patient journey, it aims to optimize diagnostics, personalize treatments, and support data-driven clinical decision-making.
“Building on lessons from previous efforts in precision oncology in Switzerland, our initiative targets the development of novel, clinically informed AI tools by seamlessly integrating a common data platform, continuously adapting robust models, and designing effective clinical interfaces and patient apps.” says Dorina Thanou, lead of the initiative at the EPFL AI Center.
Selected as a Flagship Initiative by Innosuisse, the Swiss Innovation Agency, NAIPO will unfold over four years under the leadership of the EPFL AI Center and ETH AI Center, uniting a large transdisciplinary team from a wide array of institutions including SOPHiA GENETICS, the Swiss Data Science Center (SDSC), the Swiss National Supercomputing Centre (CSCS), the Universities of Applied Sciences and Arts of Northwestern Switzerland, the Bern University of Applied Sciences, the Universities and University Hospitals of Basel, Bern, Geneva, and Zurich, Debiopharm, Roche, Switch, Tune Insight, as well as the regional hospitals of Aarau, Baden, Ticino, Luzern and Winterthur and the private clinics of Hirslanden and Swiss Medical Network. With an expected total cost of CHF 18.9 million, the project will receive approximately CHF 8.25 million in public funding from Innosuisse with the remaining amount coming from the implementation partners.
Transforming cancer research
NAIPO pioneers new AI approaches in cancer research and care, from clinical decision-support agents and large language models for records mining, to foundation models for treatment response prediction and privacy-preserving approaches. “Combined with high-throughput experimental models and patient avatars, these technologies will allow us to capture and model each patient’s uniqueness. The program will redefine AI’s role in medicine and strengthen Switzerland’s position as a leader in medical AI innovation” said Elisa Oricchio, director of the Swiss Institute of Experimental Cancer Research (ISREC) at EPFL
“Tailoring predictions and recommendations to individual patients is one of the most exciting aspects of NAIPO,” said Charlotte Bunne, professor at EPFL working on model development. “Our models will continuously learn from curated biomedical literature, as well as from individual biological and clinical data to identify potential new targets, biomarkers, and investigational drugs. Novel AI-driven insights will be integrated with clinically validated models and translated into decision-support systems.” Placing patients’ specific needs at the center of the initiative, dedicated solutions will be developed, such as a mobile app, to enhance communication and ensure patients remain actively informed and engaged throughout their care.
Deployment and long term vision
The program’s roadmap foresees clinical pilots at university and cantonal hospitals and private clinics, leading to an initial rollout at participating hospitals nationwide within four years. In addition to advancing cancer care, the infrastructure is intended to serve as a model for future applications in other disease domains.
“This initiative marks a transition toward a proactive model for precision oncology,” said Olivier Michielin, Head of Precision Oncology at Geneva University Hospitals (HUG) and Clinical Co-Coordinator of the project. “It reflects a commitment to ensuring that all patients, regardless of where they are treated within this network, benefit from the latest advances in AI-supported medicine.”
Secure, privacy-conscious collaboration is central to the initiative. Using modern data governance, the infrastructure will enable collective intelligence without centralizing sensitive health data. “We’re creating a secure and federated system that allows collaboration across institutions without compromising privacy,” said Nora Toussaint, Lead Health & Biomedical at the Swiss Data Science Center (SDSC). “Trust and transparency will be built into the design.”
“NAIPO is exactly what clinical oncology needs today. We are able to produce much more data than a couple of years ago, but we often don't know how to integrate this in actual patient care. NAIPO is instrumental to close this gap.” Says Andreas Wicki, oncology professor at the University of Zurich and Clinical Co-Coordinator of the project.
NAIPO’s long-term vision includes reducing disparities in access, accelerating the discovery of new biomarkers and treatments, and supporting sustainable innovation across the Swiss healthcare system. Milestones and key results will be shared as the project progresses.
New solution brings flexibility, efficiency, and scalability to precision oncology testing
BOSTON, MA and ROLLE, Switzerland, September 5, 2025 – SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, today announced the launch of MSK-IMPACT® Flex powered with SOPHiA DDMTM from the European Congress of Pathology. This latest innovation is designed to advance efficiencies and meaningful clinical comprehensive genomic profiling (CGP) insights. Built on the proven backbone of MSK-IMPACT® combined with the cloud-based SOPHiA DDM™ Platform, MSK-IMPACT® Flex empowers laboratories to achieve flexible, cost-efficient insights into key solid tumor biomarkers.
MSK-IMPACT® Flex powered with SOPHiA DDMTM provides a holistic view of tumor biology by enabling analysis of DNA and RNA biomarkers across all major variant classes. The solution incorporates gene expression, key signatures such as TMB, MSI, and HRD, as well as high-resolution CNV detection, allowing labs to tailor biomarker testing to each case.
“Traditional approaches to CGP often require multiple assays, leading to fragmented workflows. MSK-IMPACT® Flex powered with SOPHiA DDMTM changes that by combining expert-designed content with the adaptive analytics enabled by SOPHiA DDMTM. The result is a single, streamlined solution that delivers flexibility without compromise, helping labs advance precision oncology at scale.” said Philippe Menu, M.D., Ph.D, Chief Product Officer and Chief Medical Officer, SOPHiA GENETICS.
Key advantages of MSK-IMPACT® Flex powered with SOPHiA DDMTM include:
This launch furthers SOPHiA GENETICS’ mission to democratize data-driven medicine, bringing the latest advancements in genomic testing to healthcare institutions and patients around the world.
Learn more by connecting with SOPHiA GENETICS at the European Congress of Pathology in Vienna, Austria, September 6-9, 2025, or by visiting SOPHiAGENETICS.COM and LinkedIn.
Learn more about MSK-IMPACT® Flex powered with SOPHiA DDM™ .
Book a call to explore MSK-IMPACT® Flex powered with SOPHiA DDM™ .
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native healthcare technology company on a mission to expand access to data-driven medicine by using AI to deliver world-class care to patients with cancer and rare disorders across the globe. It is the creator of the SOPHiA DDM™ Platform, which analyzes complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions. For more information, visit SOPHiAGENETICS.COM and connect with us on LinkedIn.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact [email protected] to obtain the appropriate product information for your country of residence.
SOPHiA GENETICS Forward-Looking Statements:
This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products, and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.
Media Contact:
[email protected]
BOSTON, MA and ROLLE, Switzerland, September 5, 2025 – SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, has announced a significant new collaboration with Jessa Ziekenhuis in Hasselt, Belgium. The institutions will partner to bring cutting edge genomic testing and oncology research to cancer patients across Belgium.
Jessa Ziekenhuis, one of Belgium’s largest healthcare institutions, serves a population of over 530,000 and processes more than 3,000 oncology DNA and RNA samples annually. Through this collaboration, the hospital will adopt SOPHiA DDM™ across its pathology operations to unify its next-generation sequencing (NGS) workflows under a single platform. This full standardization, covering universal library preparation, unified automated protocols, and a fully integrated workflow, will ensure efficiency, harmonization, and compliance with national ComPerMed guidelines, while enabling more effective use of sequencing resources.
The hospital will implement six SOPHiA GENETICS applications tailored to its testing needs in solid tumors, hematologic malignancies, and liquid biopsy analysis, enhancing both clinical decision-making and research capabilities.
The SOPHiA GENETICS solution combines a cloud-based platform with embedded automation and advanced analysis tools, fully integrated with Jessa Ziekenhuis’s Laboratory Information Management System (LIMS). This ensures seamless data flow, consistency across the workflow, and significantly streamlined operations.
By unifying its entire pathology NGS operation under this single workflow, Jessa Ziekenhuis expects to cut hands-on time by 30–50%, reduce overall costs by up to 25%, and accelerate testing turnaround times. This harmonized approach also enables more efficient use of sequencers, record implementation-to-accreditation timelines, and better scalability.
Furthermore, the SOPHiA DDM™ Dispatch feature will enable Jessa Ziekenhuis to seamlessly share a NovaSeq sequencer with AZ Delta in Roeselare, Belgium. Jessa and AZ Delta jointly and equally invested in the NovaSeq, and on this foundation the two hospitals established the Bridge Consortium to provide sequencing services together. This collaborative network improves turnaround times, optimizes use of sequencing capacity, and strengthens knowledge sharing.
“At Jessa Ziekenhuis, we are strongly committed to innovation in order to provide our patients with access to the most advanced oncological care. Through our collaboration with SOPHiA GENETICS, we can fully harmonize and accelerate our NGS workflows. This step enables us to generate molecular insights faster and more accurately, which benefits both clinical decision-making and our research projects. Ultimately, this is an important investment in personalized medicine and in the quality of care for Belgian patients with cancer,” said Dr. Brigitte Maes, Clinical Pathologist at Laboratory for Molecular Diagnostics at Jessa Ziekenhuis.
“Our collaboration with Jessa Ziekenhuis exemplifies how SOPHiA GENETICS can support leading institutions in scaling their genomics capabilities while ensuring the highest possible quality and efficiency,” said Kevin Puylaert, Managing Director of EMEA, SOPHiA GENETICS. “By delivering a fully automated, cloud-native solution tailored to their oncology needs, we’re empowering Jessa Ziekenhuis to unify workflows, accelerate insights, and elevate patient care across Belgium.”
With this agreement, SOPHiA GENETICS further strengthens its footprint across European hospital networks, bringing scalable, decentralized, data-driven precision medicine to institutions advancing patient care through cutting-edge genomics. Learn more by connecting with SOPHiA GENETICS at the European Congress of Pathology in Vienna, Austria, September 6-9, 2025. For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.COM, or connect on LinkedIn.
BOSTON and ROLLE, Switzerland, August 5, 2025 – SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced an expansion of its partnership with AstraZeneca (LSE/STO/Nasdaq: AZN). This new, multi-year collaboration will leverage SOPHiA GENETICS’s multimodal AI Factories to generate evidence on the efficacy, value, and real-world impact of therapies for certain types of breast cancer. It will also support the potential development of a bespoke AI-powered predictive model aimed at optimizing outcomes for individuals undergoing treatment for breast cancer.
Derived from cutting-edge computing protocols and trained on one of the most diverse multimodal datasets in healthcare, SOPHiA GENETICS’s AI Factories offer powerful predictive insights for assessing patient prognosis and treatment response. AstraZeneca will utilize SOPHiA GENETICS’s AI Factories to analyze multimodal healthcare data — including genomics, imaging, and clinical data — and generate AI-powered insights to help optimize breast cancer outcomes. The companies will also collaborate on real-world evidence generation in Europe and North America to uncover key drivers of treatment efficacy, address critical knowledge gaps, and enhance clinical decision-making through deeper insights.
“We are proud to deepen our partnership with AstraZeneca through this significant new initiative, which highlights the growing demand for secure, compliant, and scalable real-world AI applications,” said Ross Muken, President of SOPHiA GENETICS. “Our platform is purpose-built to manage complex healthcare data environments, and this collaboration reinforces our shared commitment to driving better patient outcomes through trusted, federated analytics powered by data and AI.”
“At AstraZeneca, a core component of our AI strategy has been rooted in the deployment of frontier AI solutions across oncology clinical development,” said Jorge Reis-Filho, Chief AI and Data Scientist, AstraZeneca. “Fine tuning and augmenting our models with multimodal data – including our own data and the data that will be generated as part of this collaboration – is helping us to generate a more holistic understanding of disease biology and biomarkers to tailor the most effective treatment to patients living with cancer.”
This collaboration reinforces SOPHiA GENETICS' position as a trusted technology partner and underlines its commitment to advancing global health through federated data analytics and artificial intelligence.
For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.COM, or connect on LinkedIn.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.